A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation.
OBJECTIVES: To compare the effect of oral selegiline plus nicotine patch with placebo plus nicotine patch on smoking cessation rates. DESIGN: Randomized double-blind placebo-controlled trial. SETTING: Three community-based clinics. PARTICIPANTS: One hundred and nine male and female smokers aged 18-5...
| Publicado en: | Addiction Vol. 98; no. 10; pp. 1403 - 1408 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2003
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106710362&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106710362 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09652140 AIO jtl: Addiction issn: 09652140 maglogo: Y pubinfo: dt: Oct2003 vid: 98 iid: 10 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 106710362 106710362 2004042556 10.1046/j.1360-0443.2003.00524.x NLM14519177 106710362 ppf: 1403 ppct: 5 formats: fmt: @attributes: type: P tig: atl: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. aug: au: Biberman R Neumann R Katzir I Gerber Y affil: Clinical Research Unit, Division of Health, Maccabi Health Care Services, Tel Aviv University, Israel; rbiberman@yahoo.com sug: subj: Nicotine Patch Therapeutic Use Selegiline Therapeutic Use Smoking Cessation Adult Adverse Drug Event Analysis of Variance Chi Square Test Cotinine Urine Descriptive Statistics Double-Blind Studies Female Fisher's Exact Test Israel Male Middle Age Nicotine Urine Psychological Tests Questionnaires Selegiline Administration and Dosage Substance Withdrawal Syndrome Symptoms T-Tests Human Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: OBJECTIVES: To compare the effect of oral selegiline plus nicotine patch with placebo plus nicotine patch on smoking cessation rates. DESIGN: Randomized double-blind placebo-controlled trial. SETTING: Three community-based clinics. PARTICIPANTS: One hundred and nine male and female smokers aged 18-55 years, who smoked at least 15 cigarettes/day. INTERVENTIONS: Oral selegiline, 2.5 mg, or placebo twice/day initiated 1 week before the quit day, followed by 5 mg oral selegiline or placebo twice daily for 26 weeks, plus active nicotine skin patch to all participants for the first 8 weeks only. Measures of continuous abstinence rates up to 52 weeks, withdrawal symptoms, blood pressure and adverse events incidence. FINDINGS: Twenty-five per cent (14 of 56) were continuously abstinent for 52 weeks in the selegiline plus nicotine group compared with 11% (6 of 53) in the placebo plus nicotine group (P = 0.08). Craving for cigarettes was lower in the selegiline plus nicotine group 4 weeks after quit day (P = 0.02). CONCLUSIONS: Adding selegiline to nicotine patch was associated with a doubling of the 52-week continuous abstinence rate, but this difference was not statistically significant. Selegiline significantly reduced craving for cigarettes and appeared to mitigate the need for nicotine replacement therapy. The results suggest that selegiline is a promising drug for future smoking cessation research. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|